Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

President Trump And Drug Pricing: Rhetorical Improvement But Uncertainty Remains

Executive Summary

In his first address to Congress, President Trump didn’t drop drug pricing as a theme, but he also didn’t accuse the industry of 'getting away with murder.' For innovators, that’s at least a rhetorical improvement. Now the debate becomes what the US president means by prices that are 'artificially' high.

Advertisement

Related Content

Who Speaks For The White House On Drug Prices? Industry Better Hope It Is Not Donald Trump
Trump Slams FDA Regulations In Joint Session Of Congress
Carrots and Stick: Biopharma At The White House

Topics

Advertisement
UsernamePublicRestriction

Register

PS120134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel